BR112012024232A2 - aptâmero para ngf e uso do mesmo. - Google Patents

aptâmero para ngf e uso do mesmo.

Info

Publication number
BR112012024232A2
BR112012024232A2 BR112012024232A BR112012024232A BR112012024232A2 BR 112012024232 A2 BR112012024232 A2 BR 112012024232A2 BR 112012024232 A BR112012024232 A BR 112012024232A BR 112012024232 A BR112012024232 A BR 112012024232A BR 112012024232 A2 BR112012024232 A2 BR 112012024232A2
Authority
BR
Brazil
Prior art keywords
ngf
aptitude
aptamer
ugaaaraaacc
cgaamraaacu
Prior art date
Application number
BR112012024232A
Other languages
English (en)
Other versions
BR112012024232A8 (pt
Inventor
Hisanao Hiramatsu
Ling Jin
Yoshikazu Nakamura
Original Assignee
Ribomic Inc
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc, Shionogi & Co filed Critical Ribomic Inc
Publication of BR112012024232A2 publication Critical patent/BR112012024232A2/pt
Publication of BR112012024232A8 publication Critical patent/BR112012024232A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

aptâmero para ngf e uso do mesmo. a presente invenção refere-se a um aptâmero de maior qualidade tendo uma atividade de ligação ao ngf. um aptâmero que se liga ao ngf, o qual satisfaz (1) e (2) a seguir: (1) contém a sequência representada por ugaaaraaacc (seq id no:64) ou cgaamraaacu (seg id no:65) e (2) tem um comprimento de base de não mais do que 73.
BR112012024232A 2010-03-24 2011-03-24 "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor" BR112012024232A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010068546 2010-03-24
PCT/JP2011/057105 WO2011118682A1 (ja) 2010-03-24 2011-03-24 Ｎｇｆに対するアプタマー及びその使用

Publications (2)

Publication Number Publication Date
BR112012024232A2 true BR112012024232A2 (pt) 2016-11-29
BR112012024232A8 BR112012024232A8 (pt) 2018-02-06

Family

ID=44673231

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024232A BR112012024232A8 (pt) 2010-03-24 2011-03-24 "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"

Country Status (17)

Country Link
US (1) US9175292B2 (pt)
EP (1) EP2551346B1 (pt)
JP (1) JP5027956B2 (pt)
KR (1) KR101806429B1 (pt)
CN (1) CN102844436B (pt)
AU (1) AU2011230388B2 (pt)
BR (1) BR112012024232A8 (pt)
CA (1) CA2794199C (pt)
DK (1) DK2551346T3 (pt)
ES (1) ES2567270T3 (pt)
HR (1) HRP20160378T1 (pt)
HU (1) HUE028939T2 (pt)
IN (1) IN2012KN03036A (pt)
PL (1) PL2551346T3 (pt)
SI (1) SI2551346T1 (pt)
TW (1) TWI500425B (pt)
WO (1) WO2011118682A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598140B2 (en) 2010-04-12 2013-12-03 Somalogic, Inc. Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders
ES2687154T3 (es) 2011-09-28 2018-10-23 Ribomic Inc. Aptámero para NGF y sus aplicaciones
KR20160138215A (ko) * 2014-03-27 2016-12-02 가부시키가이샤 리보믹 오토탁신에 결합하여 오토탁신의 생리 활성을 저해하는 압타머 및 그의 이용
CN106053857A (zh) * 2015-11-29 2016-10-26 卢美珍 一种用于人脑疾病检测的试剂盒
AU2016364431B2 (en) * 2015-12-04 2020-08-27 Zenyaku Kogyo Co., Ltd. Anti-IL-17 aptamer having improved retention in blood
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CN114540349A (zh) * 2020-11-27 2022-05-27 中国科学院分子细胞科学卓越创新中心 结合yb-1蛋白的核酸分子

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
AU689087B2 (en) 1992-09-29 1998-03-26 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands and methods for producing the same
EP0724647A4 (en) 1993-09-08 2003-09-17 Gilead Sciences Inc NUCLEIC ACIDS AS LIGANDS AND IMPROVED PRODUCTION METHODS
WO2003070984A1 (en) 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
PL211654B1 (pl) 2002-10-08 2012-06-29 Rinat Neuroscience Corp Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
AU2004213044A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
RU2460794C2 (ru) 2006-11-14 2012-09-10 Рибомик Инк. Аптамер против мидкина и его применение
EP2316935B1 (en) 2008-07-14 2016-08-31 The University of Tokyo Aptamer against il-17 and use thereof
KR101694559B1 (ko) * 2008-09-24 2017-01-09 가부시키가이샤 리보믹 Ｎｇｆ에 대한 압타머 및 이의 용도

Also Published As

Publication number Publication date
IN2012KN03036A (pt) 2015-04-10
EP2551346A1 (en) 2013-01-30
US20130052176A1 (en) 2013-02-28
EP2551346B1 (en) 2016-01-27
HRP20160378T1 (hr) 2016-05-20
TW201201817A (en) 2012-01-16
CA2794199C (en) 2017-11-14
CN102844436A (zh) 2012-12-26
JP5027956B2 (ja) 2012-09-19
CN102844436B (zh) 2015-11-25
HUE028939T2 (en) 2017-01-30
ES2567270T3 (es) 2016-04-21
US9175292B2 (en) 2015-11-03
CA2794199A1 (en) 2011-09-29
TWI500425B (zh) 2015-09-21
JPWO2011118682A1 (ja) 2013-07-04
KR101806429B1 (ko) 2017-12-07
AU2011230388B2 (en) 2016-09-08
EP2551346A4 (en) 2014-04-30
KR20130028917A (ko) 2013-03-20
AU2011230388A1 (en) 2012-11-01
AU2011230388A2 (en) 2012-11-15
WO2011118682A1 (ja) 2011-09-29
SI2551346T1 (sl) 2016-05-31
BR112012024232A8 (pt) 2018-02-06
DK2551346T3 (en) 2016-04-11
PL2551346T3 (pl) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112012024232A2 (pt) aptâmero para ngf e uso do mesmo.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112016000680A2 (pt) conjugado de monômero de polipeptídeo biologicamente ativo e fragmento fc de imunoglobulina com eliminação mediada por receptor reduzida e método para a preparação do mesmo
CY1123690T1 (el) Ειδικα για cd40l ικριωματα που προερχονται απο τν3 και μεθοδοι χρησεως αυτων
BR112012006035A2 (pt) epratuzumab para uso no tratamento de uma doença autoimune ou inflamatória, e, kit
BR112018008068A2 (pt) moléculas de ligação que inibem o crescimento do câncer
BR112015019985A2 (pt) Novo análogo de insulina e sua utilização
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
MA38248A1 (fr) Compositions pesticides et procédés associés
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112014017100A2 (pt) aço estampado a quente e método para produção do aço estampado a quente
CR20110035A (es) Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5
BR112013010320B8 (pt) Composições pesticidas.
AU2016219704A1 (en) Anti-Notch1 antibodies
BR112014001591A2 (pt) apoio para o queixo, sistema de apoio do queixo e instrumento musical
BR112013018721A2 (pt) placa de desgaste integral e método
BRPI0702163A (pt) composições de toner e métodos
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
BR112014026644A2 (pt) peptídeos de agonistas de par4
BR112012027057A2 (pt) conjunto de barra de freio
BR112015009301A2 (pt) biocontrole de nematoides
BR112015000188A2 (pt) isolados de proteína de batata
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
BR112012024786A2 (pt) anticorpos humanizados il-25

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP)

B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP) , FUJIMOTO PHARMACEUTICAL CORPOR

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time